| 1.55 -0.005 (-0.32%) | 01-26 12:57 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2 | 1-year : | 2.34 |
| Resists | First : | 1.72 | Second : | 2 |
| Pivot price | 1.51  |
|||
| Supports | First : | 1.41 | Second : | 1.23 |
| MAs | MA(5) : | 1.56 |
MA(20) : | 1.45 |
| MA(100) : | 1.36 |
MA(250) : | 1.27 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 75.7 |
D(3) : | 80.8 |
| RSI | RSI(14): 53.1 |
|||
| 52-week | High : | 1.72 | Low : | 0.92 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LAB ] has closed below upper band by 44.9%. Bollinger Bands are 63.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 22 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.64 - 1.65 | 1.65 - 1.66 |
| Low: | 1.5 - 1.51 | 1.51 - 1.52 |
| Close: | 1.53 - 1.55 | 1.55 - 1.57 |
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.
Sat, 24 Jan 2026
Standard BioTools (NASDAQ:LAB) shareholders have endured a 76% loss from investing in the stock five years ago - Yahoo Finance
Sun, 18 Jan 2026
Sumitomo Mitsui Trust Group Inc. Sells 773,708 Shares of Standard BioTools Inc. $LAB - MarketBeat
Thu, 08 Jan 2026
Standard BioTools Reports Preliminary Q4, Full-Year Revenue - Nasdaq
Thu, 08 Jan 2026
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue - GlobeNewswire
Wed, 07 Jan 2026
Standard BioTools Inc. (NASDAQ:LAB) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Wed, 31 Dec 2025
Further weakness as Standard BioTools (NASDAQ:LAB) drops 15% this week, taking five-year losses to 80% - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 385 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 77.5 (%) |
| Shares Short | 10,300 (K) |
| Shares Short P.Month | 10,920 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.23 |
| Profit Margin | -75.6 % |
| Operating Margin | -29.5 % |
| Return on Assets (ttm) | -14.6 % |
| Return on Equity (ttm) | -33.3 % |
| Qtrly Rev. Growth | -14.2 % |
| Gross Profit (p.s.) | 0.21 |
| Sales Per Share | 0.44 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -188 (M) |
| PE Ratio | -3.94 |
| PEG Ratio | 0 |
| Price to Book value | 1.24 |
| Price to Sales | 3.47 |
| Price to Cash Flow | -6.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|